Actuate Therapeutics (ACTU) Q3 2024 earnings summary

Executive summary

• Focused on developing elraglusib for difficult-to-treat cancers, with ongoing Phase 2 and Phase 1/2 trials in metastatic pancreatic ductal adenocarcinoma and refractory pediatric malignancies, respectively.

• Completed IPO in August 2024, raising net proceeds of approximately $22 million, with common shares now trading on Nasdaq.

• No products approved or revenue generated to date; expects continued operating losses as development progresses.

Financial highlights

• Net loss for Q3 2024 was $6.0 million, compared to $6.3 million in Q3 2023; net loss for the nine months ended September 30, 2024 was $20.8 million, up from $17.1 million in the prior year period.

• Operating expenses for Q3 2024 were $5.4 million, down from $6.5 million in Q3 2023, primarily due to lower R&D costs.

• Cash and cash equivalents as of September 30, 2024 were $13.5 million, with working capital of $5.8 million.

• Weighted-average shares outstanding increased significantly due to IPO and conversions, impacting per-share loss calculations.

Outlook and guidance

• Current cash is not expected to fund operations for twelve months from the report date; additional capital will be required.

• Plans to finance operations through further equity, debt, or strategic arrangements; failure to secure funding may force reductions or cessation of operations.

• Expects expenses to increase as clinical development and regulatory activities expand.